The sponsor identified 3 economic studies, all in UK settings. Taylor et al. (2009) carried out a cost-effectiveness analysis on non-union tibial fractures treated by EXOGEN or by surgery ...
Bioventus Inc. posted strong Q2 results, with revenue up 10.3% and a raised full-year sales forecast. The company focuses on orthobiologics and active healing products, with key products like DUROLANE ...
The National Institute for Health and Clinical Excellence (NICE) is producing guidance on using EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback